drugset / Trial / NCT00519532
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
NaSingle-groupOpen-labelTreatment
Summary
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.
Timeline
- Start
- 2007-07
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rotigotine | Unknown | 2 mg | Other |
| Subject | Rotigotine | Unknown | 4 mg | Other |
| Subject | Rotigotine | Unknown | 6 mg | Other |
| Subject | Rotigotine | Unknown | 8 mg | Other |
| Subject | Rotigotine | Unknown | 16 mg | Other |